Blog
RSS FeedPosted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...
Posted by Michael Wonder on 01 Dec 2019
The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint
28 November 2019 - The International Network of Agencies for Health Technology Assessment (INAHTA) spans the globe as a network of ...
Posted by Michael Wonder on 26 Feb 2019
Details of Doug Ford government’s health care overhaul, including new super agency, coming Tuesday
26 February 2019 - The Ontario government will announce its long-rumoured overhaul of the province’s health care system on Tuesday, ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...
Posted by Michael Wonder on 11 Oct 2018
Ethics in health technology assessment: a systematic review
9 October 2018 - Integration of ethics into health technology assessment remains challenging for HTA practitioners. ...
Posted by Michael Wonder on 27 Jun 2018
New from CADTH: procedural guidelines and a streamlined therapeutic review framework
27 June 2018 - Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing ...
Posted by Michael Wonder on 27 Mar 2018
Gene therapy: international regulatory and health technology assessment activities and reimbursement status
28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...
Posted by Michael Wonder on 27 Mar 2018
Revamp national cancer, mental health groups, panel tells minister
27 March 2018 - Dramatic overhaul urged to role of Ottawa and its arm's-length organizations in health care. ...
Posted by Michael Wonder on 16 Jan 2018
How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy
16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare ...
Posted by Michael Wonder on 02 Oct 2017
Revised procedure for advance notification of pending CDR submissions and resubmissions
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
Posted by Michael Wonder on 01 Aug 2017
Proposed revisions to CADTH’s biosimilar review process
1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...
Posted by Michael Wonder on 13 Jul 2017
Proposed revision to the procedure for the CADTH Common Drug Review and the CADTH Therapeutic Review Framework
13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common ...
Posted by Michael Wonder on 11 Jun 2017
Subsequent entry products for non-biological complex drugs
9 June 2017 - In order to reflect the current environment for subsequent entry non-biological complex drugs, CADTH, in consultation ...
Posted by Michael Wonder on 16 May 2017
Health Minister launches high drug price consultations
16 May 2017 - Canadian drug spending has ballooned by 184% since 2000 as a share of gross domestic product. ...
Posted by Michael Wonder on 26 Oct 2016
Update to CADTH Guidelines for the Economic Evaluation of Health Technologies
27 October 2016 - CADTH's current Guidelines for the Economic Evaluation of Health Technologies (3rd edition) were published in ...